118 related articles for article (PubMed ID: 6293375)
1. Evaluation of the anti-herpesvirus drug combinations: virazole plus arabinofuranosylhypoxanthine and virazole plus arabinofuranosyladenine.
Allen LB; Vanderslice LK; Fingal CM; McCright FH; Harris EF; Cook PD
Antiviral Res; 1982 Sep; 2(4):203-16. PubMed ID: 6293375
[TBL] [Abstract][Full Text] [Related]
2. Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination.
Champney KJ; Lauter CB; Bailey EJ; Lerner AM
J Clin Invest; 1978 Dec; 62(6):1142-53. PubMed ID: 219024
[TBL] [Abstract][Full Text] [Related]
3. Therapy with 9-beta-D-arabinofuranosyladenine (ARA-A) and 2'-deoxycoformycin increases the ARA-A content of ocular tissues.
O'Brien WJ
Curr Eye Res; 1986 Aug; 5(8):595-9. PubMed ID: 3489583
[TBL] [Abstract][Full Text] [Related]
4. Deoxyadenosine antagonism of the antiviral activity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosylhypoxanthine.
Smith SH; Shipman C; Drach JC
Cancer Res; 1978 Jul; 38(7):1916-21. PubMed ID: 207416
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Kuroki Y; Shimoyama M; Inaba S; Hirose M
Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
[TBL] [Abstract][Full Text] [Related]
6. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
Plunkett W; Benjamin RS; Keating MJ; Freireich EJ
Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin.
Agarwal RP; Blatt J; Miser J; Sallan S; Lipton JM; Reaman GH; Holcenberg J; Poplack DG
Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus mutants resistant to arabinosyladenine in the presence of deoxycoformycin.
Fleming HE; Coen DM
Antimicrob Agents Chemother; 1984 Sep; 26(3):382-7. PubMed ID: 6095755
[TBL] [Abstract][Full Text] [Related]
9. Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
Shewach DS; Plunkett W
Cancer Res; 1982 Sep; 42(9):3637-41. PubMed ID: 6179604
[TBL] [Abstract][Full Text] [Related]
10. [Problems of antineoplastic effects by PLDR (potential lethal damage repair) inhibitor--pharmacokinetics].
Sougawa M; Akagi K; Yoshii G; Tanaka Y
Gan No Rinsho; 1984 Nov; 30(14):1787-92. PubMed ID: 6334757
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of phosphonoformic acid-resistant herpes simplex virus variants to arabinosylnucleosides and aphidicolin.
Bastow KF; Derse DD; Cheng YC
Antimicrob Agents Chemother; 1983 Jun; 23(6):914-7. PubMed ID: 6311091
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of arabinosyladenine in herpes simplex virus-infected and uninfected cells. Correlation with inhibition of DNA synthesis and role in antiviral selectivity.
Schwartz PM; Novack J; Shipman C; Drach JC
Biochem Pharmacol; 1984 Aug; 33(15):2431-8. PubMed ID: 6087827
[TBL] [Abstract][Full Text] [Related]
13. Effect of 2'-deoxycoformycin on the inhibition of deoxyribonucleic acid synthesis by 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
Shewach DS; Plunkett W
Biochem Pharmacol; 1982 Jun; 31(11):2103-9. PubMed ID: 6180754
[No Abstract] [Full Text] [Related]
14. Inhibitory and lethal concentrations of 9-beta-D-arabinofuranosyladenine and its hypoxanthine-derivative versus herpes simplex virus, type 1.
Williams BB; Bailey EJ; Lerner AM
J Lab Clin Med; 1977 Apr; 89(4):687-91. PubMed ID: 191546
[TBL] [Abstract][Full Text] [Related]
15. Effects of adenosine deaminase inhibitor 2'-deoxycoformycin on the repair and expression of potentially lethal damage sensitive to beta-araA.
Iliakis G; Ngo FQ
Radiat Environ Biophys; 1985; 24(2):81-8. PubMed ID: 3874406
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new adenosine deaminase inhibitor, isocoformycin, on toxicity, antitumor activity and tissue distribution of formycin A and 9-beta-D-arabinofuranosyladenine.
Hidaka T; Katayama K; Yamashita K; Yamashita T; Watanabe K; Shimazaki M; Ohno M; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1980 Mar; 33(3):303-9. PubMed ID: 7380742
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin.
Major PP; Agarwal RP; Kufe DW
Cancer Chemother Pharmacol; 1983; 10(2):125-8. PubMed ID: 6600984
[No Abstract] [Full Text] [Related]
18. Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in the presence of an adenosine deaminase inhibitor.
Schwartz PM; Shipman C; Drach JC
Antimicrob Agents Chemother; 1976 Jul; 10(1):64-74. PubMed ID: 185947
[TBL] [Abstract][Full Text] [Related]
19. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP
Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
[TBL] [Abstract][Full Text] [Related]
20. Prolongation of mouse and rat pancreatic islet cell allografts by adenosine deaminase inhibitors and adenine arabinoside.
Lum CT; Sutherland DE; Payne WD; Gorecki P; Matas AJ; Najarian JS
J Surg Res; 1980 Jan; 28(1):44-8. PubMed ID: 6767140
[No Abstract] [Full Text] [Related]
[Next] [New Search]
